ANTI-VIRAL TECHNOLOGY PLATFORM
MAVIREX is a technology platform for the development of therapies that target more than 200 different respiratory virus strains based on polymers derived from red seaweed. The first polymer of this platform is Carragelose®, a unique broadly active anti-viral compound for treating respiratory diseases that has been approved for marketing in the EU as part of an anti-viral nasal spray. It is a sulfated polymer from red seaweed also widely used in the food industry and has GRAS status (FDA).The compound has a broad spectrum of anti-viral properties and is supported with a strong patent family.
Mode of action
All viruses have one attribute in common- they all need a mechanism to enter the body of the host. Similar to the way a burdock hooks itself on to textiles, the polymer binds to the virus and in this way blocks the virus from attaching to cells.
MAVIREX targets these viruses before they can attach to the epithelia by directly binding to the viruses themselves. In this way the viruses are then hindered from attaching to cells in the respiratory tract. In the case of cells that are already infected, MAVIREX can block the spread of the infection to neighbouring cells by binding to the viruses as soon as they are released from infected cells.
Validation of MAVIREX
The MAVIREX platform has been clinically proven in children and adults by conducting three double-blind, placebo-controlled clinical trials in a natural setting with more than 450 patients enrolled including more than 200 children with an average age of 4 years.
The medication tested was a medical device nasal spray containing 1.2mg/ml Carragelose®, 0.5% NaCl in water versus a placebo saline nasal spray. Since the second clinical trial in children and the third clinical trial in adults have been conducted with similar design, both were furthermore selected for a pooled analysis. In all clinical trials the anti-viral effectiveness of MAVIREX was confirmed. Furthermore a benefit for the patient was shown in a significant reduction of the duration of the disease, a significant reduction of viral load and a significant reduction of relapses.
Figure: Relative viral load at day 3/4 in % of day 1. Shown isthe relative viral load on day 3/4 in percent of the viral load onday 1. The mean of the ct values at visit 1 was set 100% for both Iota-Carrageenan and placebo and the percent of the ct values on day 3/4 was calculated as described in materials and methods. The ct numbers of Iota-Carrageenan and placebo samples of day 1 and day 3/4 were compared by applying a Mann-Whitney U-test (p = 0.009). The black bar shows Iota-Carrageenan and the grey bar shows placebo.
Source: Efficacy and safety of an antiviral Iota-Carrageenan nasal spray: a randomized, double-blind, placebo controlled pilot study in volunteers with early symptoms of the common cold(Ron Eccles, Christiane Meier, Martez Jawad, Regina Weinmuellner, Andreas Grassauer, Eva Prieschl-Grassauer), Respiratory Research 2010.
Marinomed has successfully marketed an OTC product portfolio (medical device status in EU): an anti-viral nasal spray for the prevention and treatment of common cold, an anti-viral nasal spray for babies and an antiviral nasal spray against respiratory viral infections as influenza A. This OTC portfolio will be extended further products, as e.g. an anti-viral throat spray in 2014.
Other anti-viral therapies targeted by MAVIREX are in development and in the indications influenza, common cold as well as combination therapies in the respiratory field, especially for indications where respiratory viruses cause a worsening of the disease, such as asthma, allergic rhinitis and COPD.